T-type calcium channel (TTCC) blocker mibefradil can induce apoptosis via autophagy inhibition in drug-resistant BRAF melanoma cells, which provides a therapeutic strategy toward BRAF inhibitor resistance 179. Here, BRAF is linked to melanoma.